These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26916048)

  • 1. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers.
    Gandaglia G; Briganti A; Fossati N; Salonia A; Mottrie A; Catto J; Montorsi F
    Eur Urol; 2016 Oct; 70(4):547-548. PubMed ID: 26916048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prostate cancer - diagnostics and screening].
    Arnsrud Godtman R; Bratt O; Nordström T; Wallström J; Hugosson J
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38647107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MRI in the PSA screening era.
    George AK; Pinto PA; Rais-Bahrami S
    Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer.
    Killick E; Bancroft E; Kote-Jarai Z; Eeles R
    Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):545-55. PubMed ID: 22682955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urine-Based Test Could Help Identify Aggressive Prostate Cancer.
    Harris E
    JAMA; 2024 Jun; 331(22):1883. PubMed ID: 38758549
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of PSA density in the MRI pathway for prostate cancer diagnostics.
    Cash H; Schostak M
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):437-438. PubMed ID: 35882951
    [No Abstract]   [Full Text] [Related]  

  • 7. The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Samirae L; Krausewitz P; Alajati A; Kristiansen G; Ritter M; Ellinger J
    Int J Urol; 2024 May; 31(5):578-580. PubMed ID: 38363018
    [No Abstract]   [Full Text] [Related]  

  • 8. The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Urabe F
    Int J Urol; 2024 May; 31(5):581. PubMed ID: 38469670
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate Cancer: Genetics, Epigenetics and the Need for Immunological Biomarkers.
    Rafikova G; Gilyazova I; Enikeeva K; Pavlov V; Kzhyshkowska J
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How glycomic studies can impact on prostate cancer.
    Tkac J; Bertok T
    Expert Rev Proteomics; 2023; 20(10):189-191. PubMed ID: 37767873
    [No Abstract]   [Full Text] [Related]  

  • 11. Towards accurate genomics for newly diagnosed metastatic prostate cancer.
    Nat Cancer; 2024 Jan; 5(1):8-9. PubMed ID: 38233484
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
    Schimmöller L; Quentin M; Blondin D; Dietzel F; Hiester A; Schleich C; Thomas C; Rabenalt R; Gabbert HE; Albers P; Antoch G; Arsov C
    Eur Radiol; 2016 Nov; 26(11):3858-3864. PubMed ID: 26920391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.
    de la Taille A; Martínez-Piñeiro L; Cabri P; Houchard A; Schalken J;
    BJU Int; 2017 Jan; 119(1):74-81. PubMed ID: 26919403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Questions and answers on prostate multiparameter magnetic resonance imaging: Everything a urologist should know.
    Catalá V; Salas D; Esquena S; Mateu S; Algaba F; Palou J; de la Torre P
    Actas Urol Esp; 2016; 40(6):339-52. PubMed ID: 26920095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?
    Barbosa PV; Thomas IC; Srinivas S; Buyyounouski MK; Chung BI; Chertow GM; Asch SM; Wagner TH; Brooks JD; Leppert JT
    Eur Urol; 2016 Aug; 70(2):227-30. PubMed ID: 26948397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy.
    Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton G; Froehner M; Zastrow S; Wirth M
    BJU Int; 2016 Aug; 118(2):213-20. PubMed ID: 26935133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-Risk Prostate Cancer and Tumor Upgrading to Higher Patterns in the Surgical Specimen. Analysis of Clinical Factors Predicting Tumor Upgrading to Higher Gleason Patterns in a Contemporary Series of Patients Who Have Been Evaluated According to the Modified Gleason Score Grading System.
    Porcaro AB; Siracusano S; De Luyk N; Corsi P; Sebben M; Tafuri A; Bizzotto L; Tamanini I; Inverardi D; Cerruto MA; Martignoni G; Brunelli M; Artibani W
    Urol Int; 2016; 97(1):32-41. PubMed ID: 26998904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in prostate cancer pathology: Gleason grading and beyond.
    Shah RB; Zhou M
    Pathol Int; 2016 May; 66(5):260-72. PubMed ID: 26991008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.